Tufts Center for the Study of Drug Development modeled Medable’s agentic AI clinical monitoring platform and estimated large financial upside across oncology programs. The analysis reported expected net present value gains up to $21 million per phase 3 program, and a return on investment as high as 82x, driven by fewer on-site visits, faster enrollment timelines, and shorter closeout and database lock activities. Separately, Cleveland Clinic outlined a new partnership model aimed at scaling ambient AI medical scribes at enterprise level, describing how the health system and an industry partner built an operational framework for adoption in care settings. Together, the updates show AI moving beyond prototypes into measurable trial operations and health-system documentation workflows—supported by ROI modeling and new enterprise deployment structures.